CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 69 enrolled
Drug / intervention
AQX-1125 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01882543
NCT01882543Phase 2Completed
CompareCT.gov

A Phase 2 Study to Evaluate the Efficacy and Safety of AQX-1125 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome Mediated by the Src Homology-2-domain-containing Inositol 5' Phosphatase [SHIP1] Pathway

Aquinox Pharmaceuticals (Canada) Inc.·interventional·Posted Jun 20, 2013·Updated Sep 5, 2017

In Brief

A Phase 2 clinical trial evaluating AQX-1125 and Placebo for Interstitial Cystitis and Bladder Pain Syndrome. Completed, enrolled 69 participants across 29 sites in 2 countries.

Detailed Summary

The primary objective of this study is to evaluate the effect of 6 weeks of treatment with once daily administration of AQX-1125 compared to placebo on average daily pain in subjects with interstitial cystitis/bladder pain syndrome (IC/BPS), during and after treatment, using a standardized 11-point numerical rating scale (NRS) pain score recorded by electronic diary

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInterstitial Cystitis, Bladder Pain Syndrome
CountriesCanada, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJun 20, 2013
Enrollment StartJun 1, 2013
Primary CompletionJun 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 13.0 years ago

Interventions

AQX-1125drug

Synthetic SHIP1 activator

Placebodrug

Double blind placebo capsule